The report covers emerging Thyroid Eye Disease drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Thyroid Eye Disease treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Thyroid Eye Disease: An Overview
Thyroid Eye Disease (TED) is a complex orbital inflammatory disease, that can be sight-threatening, debilitating, and disfiguring. TED is also known as Graves’ ophthalmopathy, named after Robert J. Graves, an Irish physician who first described thyrotoxicosis in a woman presenting with goiter, rapid heartbeat, and exophthalmos.
TED affects eye muscles, eyelids, tear glands and fatty tissues behind the eye become inflamed. This can cause the eyes and eyelids to become red, swollen, and uncomfortable and the eyes can be pushed forward (‘staring’ or ‘bulging’ eyes)
Treatment of TED is based on the signs and symptoms displayed by the patient; there is no “one size fits all” approach. Generally, it is advisable to start with conservative measures, such as ocular lubrication with artificial tears, to manage symptoms of chronic irritation and redness. It is also imperative that the patient be advised to quit smoking because there is a clear link between smoking and disease activity. Medical treatment with systemic oral or pulsed intravenous corticosteroids should be reserved for patients with active inflammation resulting in increased orbital pressure, compressive optic neuropathy, severe periorbital edema, or similar presentations.
Companies all over 7MM are persistently working towards the development of novel treatment therapies that can address Thyroid eye disease. There are several promising drugs in the pipeline including VRDN—001 (Viridian Therapeutics), Secukinumab (Novartis), and IMVT-1401 (Immunovant Sciences GmbH) among others. VRDN-001 is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R).
Thyroid Eye Disease Market Key Facts
-
According to NORD, the exact prevalence (i.e. the number of people who have a disorder in a specific population at a specific time) of Thyroid Eye Disease is not known but is estimated to be 16 per 100,000 women in the general population, and 2.9 per 100,000 men in the general population.
-
The total prevalent cases of Thyroid Eye Disease in the United States were around 1,012,000 cases in 2022.
-
The US contributed to the largest prevalent population of Thyroid Eye Disease, acquiring ~42% of the 7MM in 2022. Whereas Germany accounted for around 13% and Japan accounted for around 8% of the total population share, respectively, in 2022.
-
Among EU4 countries, Germany accounted for the largest number of Thyroid Eye Disease cases, followed by France, whereas Spain accounted for the lowest number of cases in 2022.
-
According to DelveInsight estimates, there were around 16,300 cases of acute Thyroid Eye Disease and 41,900 cases of chronic Thyroid Eye Disease in Japan in 2022. These cases are projected to increase during the forecasted period.
-
In the 7MM, approximately 20% of the patient share is attributed to males, whereas only 80% of females suffer from Thyroid Eye Disease.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Thyroid Eye Disease pipeline therapies. It also thoroughly assesses the Thyroid Eye Disease market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Thyroid Eye Disease drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Thyroid Eye Disease Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Thyroid Eye Disease epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Thyroid Eye Disease epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Thyroid Eye Disease Epidemiology, Segmented as –
-
Prevalent Cases of Thyroid Eye Disease
-
Diagnosed Prevalent Cases of Thyroid Eye Disease
-
Gender-specific Diagnosed Prevalent Cases of Thyroid Eye Disease
-
Diagnosed Prevalent Cases of Thyroid Eye Disease
-
Moderate-to-severe Drug-treated Cases of Acute Thyroid Eye Disease
Thyroid Eye Disease Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Thyroid Eye Disease market or expected to be launched during the study period. The analysis covers the Thyroid Eye Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Thyroid Eye Disease drugs based on their sale and market share.
The report also covers the Thyroid Eye Disease pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Thyroid Eye Disease companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Thyroid Eye Disease Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/thyroid-eye-disease-ted-market
Thyroid Eye Disease Therapeutics Analysis
Treatment of TED is based on the signs and symptoms displayed by the patient; there is no “one size fits all” approach. Generally, it is advisable to start with conservative measures, such as ocular lubrication with artificial tears, to manage symptoms of chronic irritation and redness. It is also imperative that the patient be advised to quit smoking because there is a clear link between smoking and disease activity. Medical treatment with systemic oral or pulsed intravenous corticosteroids should be reserved for patients with active inflammation resulting in increased orbital pressure, compressive optic neuropathy, severe periorbital edema, or similar presentations.
To improve the treatment scenario, Several major pharma and biotech companies are developing therapies for Thyroid Eye Disease. Currently, Novartis is leading the therapeutics market with its Thyroid Eye Disease drug candidates in the most advanced stage of clinical development.
Thyroid Eye Disease Companies Actively Working in the Therapeutics Market Include
-
Novartis
-
Viridian Therapeutics
-
Immunovant Sciences GmbH
-
Horizon Therapeutics
And Many Others
Emerging and Marketed Thyroid Eye Disease Therapies Covered in the Report Include:
-
Secukinumab (Novartis)
-
VRDN-001 (Viridian Therapeutics)
-
IMVT-1401 (Immunovant Sciences GmbH)
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/thyroid-eye-disease-ted-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Thyroid Eye Disease Competitive Intelligence Analysis
4. Thyroid Eye Disease Market Overview at a Glance
5. Thyroid Eye Disease Disease Background and Overview
6. Thyroid Eye Disease Patient Journey
7. Thyroid Eye Disease Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Thyroid Eye Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Thyroid Eye Disease Unmet Needs
10. Key Endpoints of Thyroid Eye Disease Treatment
11. Thyroid Eye Disease Marketed Therapies
12. Thyroid Eye Disease Emerging Drugs and Latest Therapeutic Advances
13. Thyroid Eye Disease Seven Major Market Analysis
14. Attribute Analysis
15. Thyroid Eye Disease Market Outlook (In US, EU5, and Japan)
16. Thyroid Eye Disease Companies Active in the Market
17. Thyroid Eye Disease Access and Reimbursement Overview
18. KOL Views on the Thyroid Eye Disease Market
19. Thyroid Eye Disease Market Drivers
20. Thyroid Eye Disease Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/thyroid-eye-disease-ted-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Retinal Vein Occlusion Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Retinal Vein Occlusion market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Retinal Vein Occlusion market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research